Skip to Content
Merck
CN
  • Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis.

Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis.

Arteriosclerosis, thrombosis, and vascular biology (2013-07-13)
Xiaofeng Chen, Hong Lu, Mingming Zhao, Katsuya Tashiro, Lisa A Cassis, Alan Daugherty
ABSTRACT

This study determined the role of angiotensin-converting enzyme (ACE) on the development of angiotensin I-induced atherosclerosis and the contribution of leukocyte-specific expression of this enzyme. To define the contribution of ACE-dependent activity to angiotensin II synthesis in atherosclerotic development, male low-density lipoprotein receptor(-/-) mice were fed a fat-enriched diet and infused with either angiotensin I or angiotensin II. The same infusion rate of these peptides had equivalent effects on atherosclerotic development. Coinfusion of an ACE inhibitor, enalapril, ablated angiotensin I-augmented atherosclerosis but had no effect on angiotensin II-induced lesion development. ACE protein was detected in several cell types in atherosclerotic lesions, with a predominance in macrophages. This cell type secreted angiotensin II, which was ablated by ACE inhibition. To study whether leukocyte ACE contributed to atherosclerosis, irradiated male low-density lipoprotein receptor(-/-) mice were repopulated with bone marrow-derived cells from either ACE(+/+) or ACE(-/-) mice and fed the fat-enriched diet for 12 weeks. Chimeric mice with ACE deficiency in bone marrow-derived cells had modestly reduced atherosclerotic lesions in aortic arches but had no effects in aortic roots. ACE mediates angiotensin I-induced atherosclerosis, and ACE expression in leukocytes modestly contributes to atherosclerotic development in hypercholesterolemic mice.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Enalapril maleate salt, powder, ≥98% (TLC)
Supelco
Enalapril Maleate, Pharmaceutical Secondary Standard; Certified Reference Material